CDKN2A and renal cell carcinoma: The pooled OR from four studies and from one study showed that p16INK4A and p14ARF promoter methylation was not significantly associated with tumor stage in RCC (OR = 1.00, 95% CI = 0.42-2.36, P = 0.999; OR = 1.03, 95% CI = 0.18-5.98, P = 0.97, respectively) (Table 4).